study of lipolysis of visceral reserve fat using tecar therapy.

Conditions: Obesity, Visceral; Obesity; Endocrine

Summary: the scope of this study is to assess the visceral and subcutaneous fat loss in patients having tecar (radiofrequency) therapy and its effects on other anthropometric variables, adipokines and inflammation. 20 obese patients will be treated with tecar therapy (radiofrequency). each patient will have 4 active, automatic plates placed on the abdomen (200 cm2 per plate), two on the right side of the midline and two on the left side. energy will be applied for 50 minutes, controlling the temperature. subsequently, 15 minutes of capacitive and resistive manual electrodes will be applied to the abdomen, simultaneously, 20 minutes of lymphatic drainage placing one active plate in the foot and the other in the lumbo-dorsal area. patients will be informed that they will only feel comfortable warmth. five sessions will be applied from monday to friday resting saturday and sunday, for 2 weeks. total 10 sessions. subcutaneous and visceral fat will be measured by mri. anthropometric variables (body mass index, waist to hip ratio and skinfold) will be also measured. metabolic and inflammatory effects of the rf treatment will be evaluated measuring adipokines (leptin, adiponectin and resistin) as well as citokines (il-6, tnf-a and c reactive protein). results will be analyzed using the spss statistics package. a kolmogorov-smirnov test will be applied, if the data behaves normally, parametric tests will be applied. if not, non-parametric tests will be performed. the differences between proportions will be analyzed using fischer's exact test. the differences between the medians will be assessed using the student's t-test for paired samples and independent samples.

radiofrequency (rf) is an inexpensive, virtually side-effect-free, well-tolerated method that reduces belly fat. rf is a form of high-frequency electromagnetic energy that works by heating tissues (tecar therapy). its action in deeper tissues (subcutaneous layer) aims to increase cellular metabolism. when applied to tissues, rf generates oscillating magnetic fields that move electrically charged particles, producing heat in the tissues, and the amount of heat produced depends on the resistance (bioimpedance) of the target tissue. electrical energy is converted into thermal energy. there is evidence of a transient rf effect on autonomic homeostasis with no known negative effects. this autonomic response to rf is reflected in a thermoregulatory vasomotor mechanism, in changes in chemoreceptor activity, and even in fluctuations in the renin-angiotensin system, responses related to the control of energy metabolism. the elevation of tissue temperature appears to be sufficient to activate the sympathetic branch of the autonomic nervous system, leading to the release of catecholamines (adrenaline and noradrenaline), which are the trigger to activate lipolysis. lipolysis is the reversible biochemical process where triglyceride catabolism is stored. this process culminates in the generation of non-esterified fatty acids and glycerol. fatty acids released into the bloodstream can be used as a substrate to produce energy. ex vivo human skin cultures after completion of the rf treatment series showed a significant effect on subcutaneous adipocytes. adipocyte cells were observed to have altered morphology and increased expression of the apoptosis marker, apaf-1, suggesting that induced apoptosis is the mechanism of action. adipocyte apoptosis results in the release of triglycerides from disintegrated cell membranes, but in a delayed and gradual manner, allowing for slow and safe elimination through the interstitial space, and subsequent lipid transport systems, lymphatic systems, and other metabolic functions. there was no evidence of necrosis or inflammatory changes observed in adipocytes after treatments with this new rf device. obesity causes an increase in adipose tissue and an increased infiltration of inflammatory cells into that tissue with a predominance of pro-inflammatory cytokines resulting in the development of a chronic low-intensity inflammatory state. adipocytolysis is a term used to describe the phenomena caused by non-surgical techniques (cytolytic methods) for the reduction of localized fat, in which lipids could be broken or solubilized through the partial or total rupture of adipocytes, destroying their plasma membrane. frequencies around 1 mhz are used, which are the ones that act most effectively on the cell, but with a high power, adjustable temperature and a treatment area greater than 200 cm2, which allows it to mechanically destroy the adipose cells, with greater effectiveness in the subcutaneous adipose tissue without damaging the skin. blood, vessels, nerves, or connective tissues. lipids are gradually eliminated through the lymphatic system, reducing tissue volume. this procedure has been used quite effectively in aesthetics to reduce subcutaneous fat. inflammation is an orderly sequence of events designed to maintain homeostasis of organs and tissues. chronic inflammation that lasts a long time and is characterized by the presence of lymphocytes and macrophages and the proliferation of blood vessels and connective tissue. this is considered a characteristic feature of metabolic syndrome, characterized by the secretion of inflammatory adipokines usually from adipose tissue, such as leptin, interleukin (il-6), tumor necrosis factor α (tnf-α), monocyte chemoattractant protein. 1 (mcp-1) and resistin. obesity, which is a feature of metabolic syndrome, was associated with chronic inflammation in obese subjects. several inflammatory indicators are linked to obesity and shed light on the associated health complications. inflammatory indicators include il-6 and c-reactive protein (crp) as inflammatory markers and adiponectin as an anti-inflammatory marker. sustained inflammation is considered a major risk factor for developing many diseases, including cardiovascular disease, metabolic syndrome, diabetes, and cancer. as a risk factor, obesity predisposes to a pro-inflammatory state through the increase of inflammatory mediators il-6 and tnf-α, and reduced levels of adiponectin, which has a totally anti-inflammatory function. the inflammatory state followed by vascular and endothelial dysfunction is characterized by a decrease in nitric oxide and an increase in reactive oxygen species leading to oxidative stress. both states of oxidative stress and inflammation initiate atherosclerosis, hypertension, alteration of metabolic markers, and thus major adverse cardiovascular events. hence the importance of studying these markers before and after treatment. rf treatment induces an increase in the apoptotic index in adipocytes 1 hour after rf treatment. this is accompanied by a maximum temperature of 45°c in the grease layer. skin surface temperatures remain substantially lower than fat temperatures. while computed tomography (ct) is the most commonly used imaging modality for measuring abdominal fat, magnetic resonance imaging (mri) has similar accuracy. an advantage of mri is the absence of exposure to ionizing radiation, a limitation that restricts the use of ct in children and adolescents. in addition, the mri method for quantifying abdominal adiposity is effective, allowing imaging within 5 minutes. magnetic resonance imaging can provide reliable and good quality images for visceral and subcutaneous quantification. objectives main objective. to evaluate the effect of high-power resistive capacitive radiofrequency on the decrease of visceral and subcutaneous fat and changes in the lipid profile and glucaemia, serum adipokine and inflammation markers. side objectives. to evaluate and the decrease in abdominal circumferente measured by anthropometric tape measure, body mass index, waist-to-hip ratio and skinfold before and after rf treatment. methodology at the inclusion visit, the patient will be given the information sheet and, if they agree, they will be asked to sign the informed consent. once included in the study, they will be randomly assigned to one of the two study groups in order of consecutive inclusion. the project has been aprroved by the ethics committee of the autonomous university of barcelona uab. sample size calculation the aim of this study was to assess the difference between a decrease in the diameter of the abdominal circumference in a group of women, before and after radiofrequency treatment. the aim is to be able to declare a difference of 2 points or more as significant, taking the sd from published research that gives around 8.0 with a confidence level of 95%, a power of 80% and a correlation coefficient of 0.70 between the values of abdominal circumference before and after treatment. these are taken from the article published by duarte et al. in 2015, and the following results are obtained according to epidata: 15 pairs of data will then be taken: before and after the application of rf. treatment each patient will have 4 active, automatic plates placed on the abdomen (200 cm2 per plate), two on the right side of the midline and two on the left side. energy will be applied for 50 minutes, controlling the temperature. subsequently, 15 minutes of capacitive and resistive manual electrodes will be applied to the abdomen, simultaneously, 20 minutes of lymphatic drainage placing one active plate in the foot and the other in the lumbo-dorsal area. patients will be informed that they will only feel comfortable warmth. five sessions will be applied from monday to friday resting saturday and sunday, for 2 weeks. total 10 sessions. measurements (technical details for primary and secondary outcomes) * the adipose tissue volumes (cm3) of each compartment were calculated by adding the relevant voxel counts and multiplying by the voxel dimensions in cubic centimeters (cm3). the volume of adipose tissue for the entire abdomen was calculated by multiplying the volumes of adipose tissue from each slice by the sum of the thickness of the slice (5 mm) and the distance between slices. this analysis provides a direct measurement of adipose tissue volume. adipose tissue in grams is calculated from the following formula: * fat mass (g) = adipose tissue volume cm3 x 0.66 g/cm3 * body mass index is calculated as follows: body weight (kg) ÷ height (m2) * waist-to-hip ratio: according to world health organization guidelines, the waist should be measured at the midpoint between the last palpable rib and the top of the iliac crest (upper edge of the pelvis). the hip should be measured at the point of maximum circumference. both measures should be taken immediately after the air in the lungs is exhaled. the caliper takes the thickness of the abdominal wall at 5 cm in an oblique line towards the navel on the right and left side. * subcutaneous and visceral fat: will be measured using, in addition to the mri method, an inbody electrical impedance equipment, before ant after treatment. * the skinfold thickness will be measured with a calliper. * biochemical parameters: fasting blood will be drawn from the patients, to obtain serum and edta-plasma, frozen until assays. interlukin-6, tumor necrosis factor-alpha, leptin, adiponectin, resistin and ultrasensitive c-reactive protein will be determined by elisa by inmmuneassays. statistical analysis the statistical analysis of the results will be performed using the software package for social sciences (spss 24.0.). a kolmogorov-smirnov test will be applied, if the data behaves normally, parametric tests will be applied. if not, non-parametric tests will be performed. the differences between proportions will be analyzed using fischer's exact test. the differences between the medians will be assessed using the student's t-test for paired samples and independent samples.

Eligibility criteria:
inclusion criteria: * men and women. * age from 20 to 80 years. * waist circumference \> 102 cm in men and \> 88 cm in women. * bmi \> 25 kg/mt2. * visceral fat quantification \> 9 (on a scale of 20). exclusion criteria: * refusal to sign the informed consent. * pregnancy. * patients with metal prostheses. * presence of active infection. * patients with oncological history with chemotherapy treatments or radiotherapy. * presence of diabetes. * presence of metabolic disease. * presence of arterial hypertension.

Keywords: tecar therapy fat inflammation adipokines